Nordion Receives Investment Canada Act Approval and Announces Expected Closing Date for Acquisition by Sterigenics
August 01 2014 - 5:00PM
Business Wire
Nordion Inc. (TSX:NDN) (NYSE:NDZ) announced today that the
Minister of Industry has approved the previously announced proposed
acquisition of all the common shares of Nordion Inc. by
Sterigenics, pursuant to the terms of the Investment Canada Act.
This approval was the last regulatory approval required for the
proposed acquisition.
Nordion also announced that it expects the closing date of the
proposed acquisition to be on or about August 6, 2014. Upon the
completion of the acquisition, holders of Nordion common shares
will receive US$13.00 in cash in exchange for each common share
held.
A letter of transmittal is available under Nordion’s profile on
SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.
About Nordion Inc.
Nordion Inc. (TSX:NDN) (NYSE:NDZ) is a global health science
company that provides market-leading products used for the
prevention, diagnosis and treatment of disease. We are a leading
provider of medical isotopes and sterilization technologies that
benefit the lives of millions of people in more than 40 countries
around the world. Our products are used daily by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals,
clinics and research laboratories. Nordion has over 400 highly
skilled employees in three locations. Find out more at
www.nordion.com and follow us at twitter.com/NordionInc.
Caution Concerning Forward-Looking Statements
This release contains forward-looking statements, within the
meaning of certain securities laws, including under applicable
Canadian securities laws and the “safe harbour” provisions of the
United States Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
statements relating to our expectations with respect to: the timing
and outcome of the proposed acquisition by Sterigenics of all of
the outstanding common shares of Nordion; the anticipated benefits
of the transaction to the parties and their respective security
holders; Sterigenics’ ability to complete its financing; the
ability of the parties to satisfy the other conditions to, and to
complete, the transaction; the anticipated timing for the closing
of the transaction; and more generally statements with respect to
our beliefs, plans, objectives, expectations, anticipations,
estimates and intentions. The words “may”, “will”, “could”,
“should”, “would”, “outlook”, “believe”, “plan”, “anticipate”,
“estimate”, “project”, “expect”, “intend”, “indicate”, “forecast”,
“objective”, “optimistic”, and similar words and expressions are
also intended to identify forward-looking statements. In respect of
the forward-looking statements and information concerning the
anticipated benefits and completion of the proposed transaction and
the anticipated timing for the completion of the transaction,
Nordion and Sterigenics have provided such statements and
information in reliance on certain assumptions that they believe
are reasonable at this time; including the ability of the parties
to satisfy, in a timely manner, the other conditions of the closing
of the transaction; and other assumptions and expectations
concerning the transaction. There can be no assurance that the
proposed transaction will occur, or that it will occur on the terms
and conditions contemplated in this news release. The proposed
transaction could be modified, restructured or terminated.
Accordingly, readers should not place undue reliance on the
forward-looking statements and information contained in this news
release.
Since forward-looking statements and information address future
events and conditions, by their very nature they involve inherent
risks and uncertainties. Actual results could differ materially
from those currently anticipated due to a number of factors and
risks. Readers are cautioned that the foregoing list of factors is
not exhaustive. Additional information on other factors that could
affect the operations or financial results of the parties are
included in reports on file with applicable securities regulatory
authorities, including in our 2013 Annual Information Form (AIF)
and our 2014 Management Information Circular. Our 2013 AIF, 2014
Management Information Circular, and our other filings with the
Canadian provincial securities commissions and the US Securities
and Exchange Commission are available on SEDAR at www.sedar.com, on
EDGAR at www.sec.gov, and on Nordion’s website at
www.nordion.com.
The forward-looking statements contained in this news release
are made as of the date of this release and, accordingly, are
subject to change after such date. The Company does not assume any
obligation to update or revise any forward-looking statements,
whether written or oral, that may be made from time to time by us
or on our behalf, except as required by applicable law.
NordionMEDIA:Shelley Maclean, 613-592-3400 x
2414Shelley.Maclean@nordion.comorINVESTORS:Ana Raman,
613-595-4580investor.relations@nordion.com
Nordion Inc. (NYSE:NDZ)
Historical Stock Chart
From Apr 2024 to May 2024
Nordion Inc. (NYSE:NDZ)
Historical Stock Chart
From May 2023 to May 2024